Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (191)	6/24/2012 12:13:28 AM
From: tuck	Read Replies (2) \| Respond to of 210

No, this is amazing. The delta/gamma TKI may be differentiated, in that it seems more aimed at inflammation than competing compounds in the class. But does that justify $10/share over cash when that and the FAAH inhibitor are all that's left and just barely out of phase 1? Is there some IP I'm missing that would create takeout vig? Or is just taht the Baker bros. are trying not to let it crash so they can slowly get out at decent prices? Beats me. Looks like a great long term short. Cheers, Tuck